Lentiviral particles allow easy gene delivery

Published: 19-Aug-2010
Manufacturing Analysis

Supplied ready to use

AMS Biotechnology’s (AMSBIO) expression-ready lentiviral particles allow easy gene delivery into hard-to-transfect cells including primary cells, non-dividing cells and cells in suspension.

The Abingdon, UK-based firm supplies the new particles ready to use, eliminating the need for any lipids or transfection reagents. The company says these pre-made lentiviral particles are proven to deliver genes in a highly reproducible and controllable manner for the expression of more than 250 human proteins, mouse proteins, enzymes and fluorescent markers.

Using proprietary protocols based on co-expressed red fluorescent protein by a 2A peptide processing (SureTitre) or RSV promoter (Inducible system), these lentiviral particles enable real time monitoring of protein expression.

All AMSBIO lentiviral products are said to be easy and safe to use by simply adding the high titre particles (1 x 107 IFU/ml or higher) to cultured cells, and you will be able to confirm the specific target's expression under a fluorescent microscope after 48–72 hours.

AMSBIO lentiviral particles are packaged in culture medium with 10% FBS, in serum-free medium or concentrated in PBS for in vivo use.

See more

You may also like

Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

Read more
New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  4. See. Try. Believe. Experience the Lyza 7000 FTIR with a 70-day risk free trial Laboratories can now evaluate the Lyza 7000 FTIR spectrometer in their own environment through a new 70-day, no-cost, no-risk trial program. The initiative allows teams to run real samples, follow existing SOPs, and fully explore the instrument’s capabilities before making a purchase decision
  5. Andelyn Biosciences and ENCell partner to create US-APAC gene therapy manufacturing corridor The company has signed a collaboration agreement with South Korea's ENCell to establish a dual-hemisphere manufacturing platform linking US and Asia-Pacific facilities, enabling in-country production for regional clinical trials

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Analysis

Introducing Shimadzu’s MultiNA II: Redefining precision in life science analysis

Designed with users in mind, the MultiNA II MCE-301 is a fully automated microchip electrophoresis system designed to accelerate and simplify genetic analysis workflows in pharmaceutical and biopharmaceutical laboratories
Manufacturing

Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform

The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Manufacturing

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services collaborate to support ADC development and manufacturing

Piramal and Ajinomoto Bio-Pharma Services have entered a collaborative arrangement aimed at enhancing their customers’ ADC development and manufacturing programs
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Subscribe now